Zika Vaccine Timeline: Will It Be Too Little Too Late?
Following the Zika outbreak in Latin America in late 2015, a number of pharmaceutical companies have stepped up their vaccine research efforts against a virus that has now been scientifically determined as the cause of microcephaly and other severe brain defects in babies. But will a product be able to reach the market soon enough to have an impact on the current outbreak?
You may also be interested in...
Aduro hopes for a relatively quick resolution to a clinical hold for its LADD cancer vaccine studies instituted by the FDA based on listeria detected around indwelling ports in two patients.
When Scrip first wrote about Zika virus (ZIKV) less than two weeks ago there was no record of any clinical development ongoing for a treatment or vaccine against the mosquito-transmitted disease, let alone any available therapies.
The pharma industry's (and the media's) interest in Ebola has begun to wane as more affected African countries secure disease-free status from the World Health Organization, but another tropical condition has started to capture headlines – Zika virus (ZIKV), a mosquito transferred disease reportedly responsible for approximately 4,000 child birth defects since Oct. 2015.